Aclarion, Inc. (NASDAQ:ACON – Get Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 19,700 shares, a decline of 50.8% from the August 15th total of 40,000 shares. Based on an average trading volume of 544,400 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.4% of the shares of the stock are sold short.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Aclarion stock. Captrust Financial Advisors bought a new stake in Aclarion, Inc. (NASDAQ:ACON – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 78,400 shares of the company’s stock, valued at approximately $61,000. Captrust Financial Advisors owned approximately 1.00% of Aclarion at the end of the most recent quarter. Institutional investors and hedge funds own 7.52% of the company’s stock.
Aclarion Price Performance
Aclarion stock opened at $0.40 on Thursday. The company’s 50 day simple moving average is $0.55 and its 200-day simple moving average is $0.72. Aclarion has a 1 year low of $0.36 and a 1 year high of $2.37.
Aclarion Company Profile
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
- Five stocks we like better than Aclarion
- What is Put Option Volume?
- Is Enbridge Stock Too Cheap to Pass Up Now?
- How to Invest in Insurance Companies: A Guide
- 5 Best REIT Alternatives for Passive Real Estate Income
- How to Invest and Trade Chinese Stocks
- 5 Reasons Kroger Should Be On Every Income Investor Watchlist
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.